Knopp Biosciences
Knopp Biosciences, a US-based company, innovates breakthrough neurological disorder treatments, with a lead compound in development.
Founded
2004Knopp Biosciences, a US-based company, innovates breakthrough neurological disorder treatments, with a lead compound in development.
Knopp Biosciences is a drug discovery and development company based in Pittsburgh, United States, focused on delivering breakthrough treatments for neurological disorders. The company leverages innovation, experience, and partnerships to advance its mission. Knopp’s lead compound, KNS-760704, is in clinical development, and the company also manages a portfolio of equity securities and future product royalties. Their clinical-stage oral small molecule, dexpramipexole, is being developed for eosinophilic asthma by Areteia Therapeutics.
Knopp Biosciences has made significant strides in the field of drug discovery, particularly in challenging immunological and neurological diseases. Their Kv7 platform of small molecules is in the clinical stage, showcasing their commitment to advancing medical science. Notably, Areteia Therapeutics, a portfolio company of Bain Capital Life Sciences, is developing one of Knopp’s compounds, highlighting the company's impactful collaborations and contributions to innovative healthcare solutions.
Companies similar to Knopp Biosciences include KBP Biosciences, Areteia Therapeutics, Harmony Biosciences and Bioscience Pharma Partners.
Knopp Biosciences was founded in 2004.
Knopp Biosciences' headquarters is located in Pittsburgh, PA, US.
Knopp Biosciences' most recent funding round was for $14M (USD) in November 2020.
As of Nov 11, 2020, Knopp Biosciences has disclosed funding of $164M (USD). Undisclosed round amounts are excluded.
Knopp Biosciences has 10 employees as of Feb 5, 2024.
Bioscience Pharma Partners
